News | June 26, 2021
Shilpa Medicare receives DRDO approval for 2DG manufacturing
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Shilpa's Paracetamol oral thin films are patent protected and are first of this kind in the world
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The GMP certificate is valid for three years until April 2024.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The commercial production in the SML was started in November 1989.
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
he inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Subscribe To Our Newsletter & Stay Updated
